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Double-Dose Versus Standard-Dose Clopidogrel According to
Smoking Status Among Patients With Acute Coronary Syndromes
Undergoing Percutaneous Coronary Intervention
Matthias Bossard, MD; Christopher B. Granger, MD; Jean-Francois Tanguay, MD; Gilles Montalescot, MD, PhD; David P. Faxon, MD;
Sanjit S. Jolly, MD, MSc; Petr Widimsky, MD; Kari Niemela, MD; Philippe Gabriel Steg, MD; Madhu K. Natarajan, MD, MSc; Peggy Gao, MSc;
Keith A. A. Fox, MD, MBChB; Salim Yusuf, MD, DPhil; Shamir R. Mehta, MD, MSc
Background-—Prior Studies have suggested better outcomes in smokers compared with nonsmokers receiving clopidogrel
(“smoker’s paradox”). The impact of a more intensive clopidogrel regimen on ischemic and bleeding risks in smokers with acute
coronary syndromes requiring percutaneous coronary interventions remains unclear.
Methods and Results-—We analyzed 17 263 acute coronary syndrome patients undergoing percutaneous coronary intervention
from the CURRENT-OASIS 7 (Clopidogrel and Aspirin Optimal Dose Usage to Reduce Recurrent Events—Seventh Organization to
Assess Strategies in Ischemic Symptoms) trial, which compared double-dose (600 mg day 1;150 mg days 2–7; then 75 mg
daily) versus standard-dose (300 mg day 1; then 75 mg daily) clopidogrel in acute coronary syndrome patients. The primary
outcome was cardiovascular death, myocardial infarction, or stroke at 30 days. Interactions between treatment allocation and
smoking status (current smokers versus nonsmokers) were evaluated. Overall, 6394 patients (37.0%) were current smokers. For
the comparison of double- versus standard-dose clopidogrel, there were signiﬁcant interactions in smokers and nonsmokers for
the primary outcome (P=0.031) and major bleeding (P=0.002). Double- versus standard-dose clopidogrel reduced the primary
outcome among smokers by 34% (hazard ratio [HR] 0.66, 95% conﬁdence interval [CI], 0.50–0.87, P=0.003), whereas in
nonsmokers, there was no apparent beneﬁt (HR 0.96, 95% CI, 0.80–1.14, P=0.61). For major bleeding, there was no difference
between the groups in smokers (HR 0.77, 95% CI, 0.48–1.24, P=0.28), whereas in nonsmokers, the double-dose clopidogrel
regimen increased bleeding (HR 1.89, 95% CI, 1.37–2.60, P<0.0001). Double-dose clopidogrel reduced the incidence of deﬁnite
stent thrombosis in smokers (HR 0.41, 95% CI, 0.24–0.71) and nonsmokers (HR 0.63, 95% CI, 0.42–0.93; P for
interaction=0.19).
Conclusions-—In smokers, a double-dose clopidogrel regimen reduced major cardiovascular events and stent thrombosis after
percutaneous coronary intervention, with no increase in major bleeding. This suggests that clopidogrel dosing in patients with
acute coronary syndromes should be personalized, taking into consideration both ischemic and bleeding risk.
Clinical Trial Registration-—URL: https://www.clinicaltrials.gov. Unique identiﬁer: NCT00335452. ( J Am Heart Assoc. 2017;6:
e006577. DOI: 10.1161/JAHA.117.006577.)
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S moking is one of the most important preventable riskfactors for ischemic heart disease and cardiovascular
mortality in the general population.1 Among patients
presenting with acute coronary syndromes (ACS), smokers
are usually younger and have fewer concomitant health
issues, and represent a distinct, but also vulnerable cohort
with respect to long-term prognosis. Earlier studies have
suggested better short-term outcomes among smokers
with myocardial infarction (MI), a phenomenon known as
the “smoker’s paradox.”2–6 This may be because of the
lower age and baseline risk proﬁle in smokers compared
with nonsmokers. However, recent studies have highlighted
the detrimental inﬂuence of smoking on short- and long-
term outcome in ACS patients, with a substantially higher
risk for re-infarction, stent thrombosis, and death in
smokers, irrespective of age.7–13
ADP receptor blockers, including clopidogrel, reduce the
risk for repeat MI, stroke, and cardiovascular death in patients
with an ACS.14–16 They also reduce the risk for stent
thrombosis after percutaneous coronary interventions (PCI)
and stenting.14–16 Despite the advent of new ADP–receptor
blockers, such as prasugrel and ticagrelor, clopidogrel
remains the most commonly administered thienopyridine
after stent placement in most countries. Furthermore, the
CURRENT-OASIS 7 (Clopidogrel and Aspirin Optimal Dose
Usage to Reduce Recurrent Events—Seventh Organization to
Assess Strategies in Ischemic Symptoms) trial has shown that
a 7-day double-dose, compared with a standard-dose, regimen
of clopidogrel effectively reduced ischemic events and stent
thrombosis among patients undergoing PCI for ACS.16
Nevertheless, several studies, including data from the
clopidogrel landmark trials, suggested differing outcomes
among current smokers versus nonsmokers receiving clopi-
dogrel treatment for various cardiovascular conditions (ie,
unstable angina or atherosclerotic vascular disease), whereas
smoking patients apparently derived greater beneﬁt from
clopidogrel.17,18 These results led to some controversies
about the “smoker’s paradox” in the context of clopidogrel
treatment and its efﬁcacy in current smokers versus
nonsmokers.17,18
So far, it is uncertain whether a higher clopidogrel dose
mitigates the elevated risk for early adverse events including
stent thrombosis encountered in current smokers with an
ACS undergoing PCI. Therefore, our aim was to assess the
inﬂuence of a double-dose clopidogrel regimen on clinical
outcomes among current smokers versus nonsmokers with
ACS undergoing PCI from the CURRENT-OASIS-7 trial.
Methods
Study Design and Patients
This analysis represents a prespeciﬁed subgroup analysis of
the CURRENT-OASIS 7 trial comparing high-dose versus
standard-dose of aspirin and clopidogrel in ACS. This 292
factorial trial was conducted between June 2006, and July
2009 at 597 centers in 39 countries. The detailed method-
ology and the trial’s main result have been published earlier.14–
16 In brief, we included patients who had an ACS (with or
without ST-segment elevation) conﬁrmed by elevated cardiac
enzymes and electrocardiographic evidence of ischemia.
Patients were eligible if they were scheduled for early coronary
angiography with an intention for PCI, no later than 72 hours
after randomization. Our main exclusion criteria were an
increased risk of bleeding or active bleeding.14
Clinical Perspective
What Is New?
• We evaluated the efﬁcacy of a standard-dose (75 mg/d)
compared with a 7-day double-dose (150 mg/d) regimen of
clopidogrel in current smokers and nonsmokers with acute
coronary syndromes (ACS) requiring percutaneous coronary
interventions.
• Compared with the standard dose, the 7-day double-dose
regimen of clopidogrel reduced the rate of major cardio-
vascular events in the ACS setting signiﬁcantly, more among
current smokers than in nonsmokers.
• The higher dosing strategy appeared to have less of an
effect on increased risk for major bleeding in current
smokers than in nonsmokers.
• The double-dose clopidogrel strategy appeared to be
particularly effective in heavy smokers (consuming ≥20
cigarettes/d).
What Are the Clinical Implications?
• Smoking is one of the most important preventable risk
factors for atherosclerotic diseases and ischemic heart
disease, and smoking has a detrimental inﬂuence on short-
and long-term outcomes in ACS patients.
• It was uncertain whether a higher clopidogrel dose mitigates
the elevated risk for early adverse events encountered in
current smokers with ACS requiring percutaneous coronary
interventions.
• According to our data, a more intensive antiplatelet
inhibition may be especially beneﬁcial in smokers present-
ing with ACS who are referred for early percutaneous
coronary intervention.
• Our data also suggest that a personalized clopidogrel-dosing
strategy considering risk factors for early adverse outcomes
after percutaneous coronary interventions in ACS patients
should be applied.
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For the present analysis, we included 17 263 patients who
underwent a PCI procedure for their index MI with a known
smoking status, which represents a subset of the 25 086
patients in the trial, of whom 7823 did not undergo early PCI,
and 7 of those undergoing PCI did not have smoking status
data available. We deﬁned the smoking status as follows:
current smokers were considered as patients smoking at least
1 cigarette (or cigar, or pipe) per day within 30 days and up to
the time of admission for their ACS; and nonsmoking patients
were deﬁned as former smokers and individuals who never
smoked. We also grouped current smokers according to their
tobacco/cigarettes consumption, as follows: <10, 10 to 19,
and ≥20 cigarettes/d.
The patients had to provide written informed consent to
participate. This trial complied with the Declaration of
Helsinki. All national regulatory authorities and the ethics
committees at the participating centers approved it. This trial
was registered with ClinicalTrials.gov, number NCT00335452.
The trial was coordinated by the Population Health
Research Institute (McMaster University and Hamilton Health
Sciences, Hamilton, ON, Canada), which independently man-
aged the database and performed the primary data analyses.
An operations committee, with assistance from an interna-
tional steering committee and with participation of the
sponsor, was responsible for the design, conduct, and
reporting of the study. All authors had full access to all the
data in the study and had responsibility for the decision to
submit the report for publication.
Randomization, Procedures, and Outcomes
The patients were randomized by a 24-hour central automated
voice response system. We used permuted block randomiza-
tion stratiﬁed by center.14–16 A statistician set up a computer-
generated random allocation sequence for the data safety and
monitoring board. For the clopidogrel dose allocation,
patients, those doing the interventions, those evaluating
events, and those analyzing the data were masked to group
assignment. The aspirin dose allocation was open label, with
blinded adjudication of outcomes.
After randomization and before the cardiac catheterization,
the patients, who were randomly allocated to double-dose
clopidogrel, received a 600-mg loading dose on day 1
followed by 150 mg once daily on days 2 to 7. Those
assigned to standard-dose clopidogrel received a 300-mg
loading dose on day 1 followed by 75 mg once daily on days 2
to 7. Subsequently, on days 8 to 30, both groups received
75 mg once daily.14–16
All participants received a loading dose of aspirin
(≥300 mg) on day 1. On days 2 to 30, patients randomly
allocated low-dose aspirin received 75 to 100 mg daily,
whereas those allocated high-dose aspirin received 300 to
325 mg daily. We strongly discouraged the administration of
vitamin K antagonists concurrently with the study drugs
during the ﬁrst 7 days. The other therapies, including
anticoagulants, glycoprotein IIb/IIIa antagonists, and the
applied stents, were left to the discretion of the treating
physician.
Our primary outcome was the composite of cardiovascular
death, MI, or stroke from randomization to day 30.14–16
Secondary outcomes included the primary outcome plus
recurrent ischemia, individual components of the composite
outcomes, and stent thrombosis as deﬁned by the academic
research consortium.14–16 The applied deﬁnitions of outcome
events have been described elsewhere.14 A central commit-
tee, blinded for the treatment allocation, adjudicated all
efﬁcacy outcomes, including recurrent ischemia, stent throm-
bosis, and bleeding events.
Statistical Analysis
The analyses were performed using SAS version 9.4 (SAS
Institute, Cary, NC). For comparison of the baseline demo-
graphics according to smoking status (nonsmokers versus
current smokers), differences in continuous variables were
analyzed by t tests, Mann–Whitney U test, and differences in
categorical variables by v2 tests.
All our analyses were based on the intention-to-treat
principle. Efﬁcacy and safety analyses were performed with
Cox proportional hazards models including terms for treat-
ment group and stratiﬁed for admission diagnosis (unstable
angina/non-ST-segment elevation myocardial infarction or
ST-segment elevation myocardial infarction [STEMI]), aspirin
dose, and tertiles of a propensity score for current smoking
status in patients undergoing PCI. In order to account for the
difference in baseline characteristics between current smok-
ers and nonsmokers, we used a dedicated propensity scoring
system for adjustment of the Cox proportional hazards
models.
The applied propensity score was derived by using a logistic
regression model predicting the probability of current smoking
in patients undergoing PCI (n=17 256). We considered the
following patient-based baseline variables: age, sex, blood
pressure, heart rate, time from symptom onset to randomiza-
tion, treatment allocation, admission diagnosis ([STEMI] versus
unstable angina/non-ST-segment elevation myocardial infarc-
tion), pre-randomization anticoagulant use (unfractionated
heparin, low-molecular-weight heparin, fondaparinux, glyco-
protein IIb/IIIa antagonists), pre-randomization use of b-
blockers, angiotensin-converting enzyme inhibitors, angioten-
sin receptor blockers, statins, calcium channel blockers, region
(North America/Australia/New Zealand, South America,
Western Europe/South Africa, Central and Eastern Europe,
Asia), baseline ECG (ST-segment elevation, new left bundle
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branch block, ST-segment depression, T-wave inversion, tran-
sient ST-segment elevation, none), baseline location of ECG
changes (anterior, inferior, other), pre-randomization use of
clopidogrel (none, <300 mg, ≥300 mg), pre-randomization use
of aspirin, elevated cardiac biomarker, baseline hemoglobin,
baseline heart failure (no or yes; if yes, Killip class), prior history
of hypertension, dyslipidemia, diabetes mellitus, MI, PCI, or
coronary artery bypass graft.
We tested for collinearity among the included variables.
The maximum variance inﬂation factor was 3; therefore,
multicollinearity does not appear to be a concern. Addition-
ally, interaction tests were performed to assess the efﬁcacy of
the clopidogrel regimens in ACS patients with differing
smoking patterns and intensity (nonsmokers, current smokers
consuming <10, 10–19, and ≥20 cigarettes/d). Additionally,
interaction tests were performed to assess the efﬁcacy of the
clopidogrel regimens in ACS patients with differing smoking
patterns and intensity (nonsmokers, current smokers con-
suming <10, 10 to 19, and ≥20 cigarettes/d). Finally, survival
curves for the primary outcome and major bleeding events
were charted by Kaplan–Meier analyses and the outcomes
were compared using log-rank tests. A P<0.05 was consid-
ered statistically signiﬁcant.
Results
The baseline characteristics of the 17 263 analyzed patients
presenting with ACS and treated with PCI are displayed in
Table 1. The mean age was 61.211.7 years, 2188 patients
(12.7%) were older than 75 years, and 13 029 patients
(75.5%) were male. Unstable angina/non-ST-segment eleva-
tion myocardial infarction and STEMI presentation were found
in 10 899 and 6364 patients, respectively. Overall, 16 323
(94.6%) underwent stent implantation, whereas 9457 (57.9%)
received bare-metal stents and 6866 (42.1%) had implanted at
least 1 drug-eluting stent. Baseline demographics were
basically balanced between the randomly allocated treatment
groups (standard versus double-dose clopidogrel regimen);
only the number of patients treated with b-blockers and
angiotensin-2 receptor blockers differed (P=0.009 and
P=0.043, also highlighted in the Tables S1 and S2).
Current smokers (n=6394) were signiﬁcantly younger,
more frequently males, and more often had a STEMI
presentation. They also had fewer comorbidities, including
diabetes mellitus, hypertension, dyslipidemia, and established
coronary artery disease (Table 1). Current smokers also
received more frequently glycoprotein IIb/IIIa inhibitors. The
primary outcome, including cardiovascular death, MI, or
stroke, did not signiﬁcantly differ between current smokers
compared with nonsmokers (204 [3.2%] versus 514 [4.7%];
adjusted hazard ratio [HR] 0.91, 95% conﬁdence interval [CI],
0.76–1.09, P=0.30, respectively, Table 2). There was no
signiﬁcant difference in rates of stent thrombosis between
current smokers and nonsmokers (112 [1.8%] versus 221
[2.0%]; HR 1.03, 95% CI, 0.80–1.33, P=0.80). Overall,
nonsmokers, in comparison to current smokers, showed a
trend for a higher rate of major bleedings (166 [1.5%] versus
71 [1.1%]; HR 1.32, 95% CI, 0.97–1.79, P=0.077), as
displayed in Table 2.
Focusing on the efﬁcacy of double- versus standard-dose
clopidogrel, the primary outcome occurred in 330 (3.9%)
patients treated with the double-dose regimen and in 392
(4.5%) patients receiving the standard dose (HR 0.86, 95% CI,
0.74–1.00, P=0.051; Figure 1). However, there was a signif-
icant treatment interaction in active smokers and nonsmokers
for the primary outcome (P for interaction=0.031). Double-
versus standard-dose clopidogrel resulted in a 34% reduction
of the primary outcome among current smokers (HR 0.66,
95% CI, 0.50–0.87, P=0.003), whereas in nonsmokers, there
was no apparent beneﬁt (HR 0.96, 95% CI, 0.80–1.14,
P=0.61), as shown in Figure 1. This treatment effect was
furthermore highlighted among our survival analyses for the
primary outcome. (Figure 2A).
With regard to safety, the double- compared with the
standard-dose clopidogrel regimen increased the risk for
severe and major bleeding (96 [1.1%] versus 72 [0.8%]; HR
1.38, 95% CI, 1.02–1.88, P=0.038; and 139 [1.6%] versus 99
[1.1%]; HR 1.45, 95% CI, 1.12–1.88), P=0.005, respectively),
as displayed in Figure 1. For major bleeding, there was a
signiﬁcant treatment interaction between current smokers
and nonsmokers receiving either the double or standard
clopidogrel dose (P for interaction=0.002). There was no
apparent difference between the clopidogrel dosing groups in
current smokers (31 [1.0%] versus 40 [1.3%]; HR 0.77, 95% CI,
0.49–1.24, P=0.28), whereas in nonsmokers, the double-
compared with standard-dose clopidogrel regimen signiﬁ-
cantly increased major bleeding (107 [2.0%] versus 59 [1.1%];
HR 1.89, 95% CI, 1.37–2.60, P<0.0001, Figure 1). A similar
trend was found for severe bleeding (P for interaction=0.058).
The different impact of the 2 clopidogrel-dosing strategies on
major bleedings in current smokers and nonsmokers is also
highlighted in Figure 2B.
Overall, administration of a double- compared with a
standard-dose clopidogrel regimen resulted in a reduction of
new MI or stent thrombosis (251 [2.9%] versus 322 [3.7%]; HR
0.80, 95% CI, 0.68–0.95, P=0.009). The double- versus
standard-dose of clopidogrel led to a 30% reduction in stent
thrombosis (135 [1.6%] versus 200 [2.3%]; HR 0.70, 95% CI,
0.56–0.87, P=0.001), as displayed in Figure 1. In fact, the
double- versus standard-dose regimen reduced the incidence
of deﬁnite stent thrombosis in current smokers (18 [0.6%]
versus 44 [1.4%]; HR 0.41, 95% CI, 0.24–0.71, P=0.001) and
nonsmokers (40 [0.8%] versus 66 [1.2%]; HR 0.63, 95% CI,
0.42–0.93, P=0.021; P for interaction=0.19).
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Table 1. Baseline Characteristics Grouped by Smoking Status and Clopidogrel Regimens (Standard Vs Double-Dose)
Current Smokers Nonsmokers*
Overall
Standard-Dose
Clopidogrel Regimen
Double-Dose
Clopidogrel Regimen
P Value†
Standard-Dose
Clopidogrel Regimen
Double-Dose
Clopidogrel Regimen
P Value†(n=17 263) (n=3189) (n=3205) (n=5513) (n=5349)
Age, y 61.211.7 55.39.8 55.310.1 0.94 64.611.1 64.611.2 0.94
Age >75 y, % 2188 (12.7) 92 (2.9) 94 (2.9) 0.91 999 (18.1) 1000 (18.7) 0.44
Males, % 13 029 (75.5) 2668 (83.7) 2701 (84.3) 0.51 3851 (69.9) 3804 (71.1) 0.15
Presentation, %
STEMI 6364 (36.9) 1432 (44.9) 1457 (45.5) 0.65 1750 (31.7) 1719 (32.1) 0.66
UA/NSTEMI 10 899 (63.1) 1757 (55.1) 1748 (54.5) 0.65 3763 (68.3) 3630 (67.9) 0.66
Comorbidities, %
Diabetes mellitus, % 3844 (22.3) 476 (14.9) 498 (15.5) 0.49 1457 (26.4) 1411 (26.4) 0.95
Hypertension, % 10 197 (59.1) 1495 (46.9) 1536 (47.9) 0.39 3622 (65.7) 3540 (66.2) 0.59
Dyslipidemia, % 6953 (40.3) 1115 (35) 1175 (36.7) 0.15 2391 (43.4) 2270 (42.5) 0.33
Previous MI, % 2933 (17.0) 363 (11.4) 412 (12.9) 0.071 1096 (19.9) 1061 (19.8) 0.95
Previous PCI, % 2515 (14.6) 308 (9.7) 305 (9.5) 0.85 956 (17.3) 945 (17.7) 0.65
Peripheral arterial
disease, %
753 (4.4) 135 (4.2) 134 (4.2) 0.92 246 (4.5) 236 (4.4) 0.90
Antithrombotics before randomization, %
Aspirin 6444 (37.3) 787 (24.7) 793 (24.7) 0.95 2450 (44.4) 2412 (45.1) 0.49
Clopidogrel 3494 (20.2) 464 (14.6) 509 (15.9) 0.14 1291 (23.4) 1228 (23.0) 0.57
Unfractionated heparin 6685 (38.7) 1205 (37.8) 1238 (38.6) 0.49 2165 (39.3) 2071 (38.7) 0.54
LMWH 6619 (38.4) 1315 (41.2) 1256 (39.2) 0.095 2008 (36.4) 2039 (38.1) 0.071
Fondaparinux 599 (3.1) 115 (3.6) 102 (3.2) 0.35 193 (3.5) 189 (3.5) 0.93
GP IIbIIIa inhibitors 4383 (25.4) 893 (28.0) 887 (27.7) 0.77 1299 (23.6) 1301 (24.3) 0.36
Fibrinolytics‡ 534 (8.4) 126 (8.8) 131 (9.0) 0.86 144 (8.2) 133 (7.8) 0.59
Antithrombotics administered during PCI and hospital admission, %
Unfractionated heparin 15 151 (87.8) 2789 (87.5) 2853 (89) 0.053 4834 (87.7) 4669 (87.3) 0.53
LMWH 8628 (50.0) 1707 (53.5) 1674 (52.2) 0.30 2598 (47.1) 2646 (49.5) 0.015
Fondaparinux 779 (4.5) 141 (4.4) 133 (4.1) 0.59 259 (4.7) 246 (4.6) 0.81
Bivalirudin 960 (5.6) 148 (4.6) 154 (4.8) 0.76 331 (6.0) 327 (6.1) 0.82
GP IIbIIIa inhibitors 7010 (40.6) 1387 (43.5) 1397 (43.6) 0.94 2120 (38.5) 2103 (39.3) 0.36
Postrandomization therapy, %
b-Blockers 14 555 (84.3) 2685 (84.2) 2735 (85.3) 0.21 4590 (83.3) 4542 (84.9) 0.019
ACE-inhibitors 11 989 (69.5) 2269 (71.2) 2281 (71.2) 0.99 3759 (68.2) 3678 (68.8) 0.53
AT-2-antagonists 1588 (9.2) 224 (7) 201 (6.3) 0.23 615 (11.2) 547 (10.2) 0.12
Ca-channel blockers 2352 (13.6) 333 (10.4) 320 (10) 0.55 864 (15.7) 835 (15.6) 0.93
Statins 15 575 (90.2) 2927 (91.8) 2932 (91.5) 0.66 4932 (89.5) 4780 (89.4) 0.85
Proton-pump inhibitors 5295 (39.9) 1044 (40.4) 1043 (39.8) 0.65 1607 (39.1) 1599 (40.5) 0.22
Lesions treated, % 17 670 (100) 3174 (100) 3248 (100) – 5727 (100) 5521 (100) –
Left main 278 (1.6) 49 (1.5) 38 (1.2) 91 (1.6) 100 (1.8)
Left anterior descending 6131 (34.7) 1000 (31.5) 1055 (32.5) 2053 (35.8) 2023 (36.6)
Left circumflex 4657 (26.4) 878 (27.7) 880 (27.1) 1498 (26.2) 1401 (25.4)
Right coronary artery 6159 (34.8) 1217 (38.3) 1235 (38.0) 1906 (33.3) 1801 (32.6)
Continued
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Evaluating the efﬁcacy of double- versus standard-dose
clopidogrel in ACS patients with differing smoking patterns
(nonsmokers, current smokers consuming <10, 10–19, and
≥20 cigarettes/d), we found signiﬁcant treatment interac-
tions with regard to the primary outcome, risks for repeat MI,
stent thrombosis, and major bleedings (P for interactions
0.016, 0.026, 0.017, and 0.018, respectively) among those
groups, as shown in Table 3. In comparison to non-, light-, and
moderate smokers, heavy smokers (consuming ≥20 ci-
garettes/d) showed a highly signiﬁcant reduction of the
primary end point, the rates of MI and stent thrombosis (P for
all <0.0001), without relevant increase in bleeding risk, if
treated with a double- compared with a standard-dose
clopidogrel regimen (Table 3).
Discussion
In this large cohort of patients with ST- and non-ST-segment
elevation ACS undergoing early PCI in the CURRENT-OASIS 7
trial, we found that a 7-day double-dose regimen of clopido-
grel, in comparison with the standard dose, had signiﬁcantly
greater beneﬁt in reducing the primary outcome in current
Table 1. Continued
Current Smokers Nonsmokers*
Overall
Standard-Dose
Clopidogrel Regimen
Double-Dose
Clopidogrel Regimen
P Value†
Standard-Dose
Clopidogrel Regimen
Double-Dose
Clopidogrel Regimen
P Value†(n=17 263) (n=3189) (n=3205) (n=5513) (n=5349)
Saphenous vein/arterial
graft
445 (2.5) 30 (0.9) 40 (1.2) 179 (3.1) 196 (3.6)
Visible angiographic
thrombus before PCI
5465 (32.8) 1152 (37.3) 1200 (38.7) 0.27 1595 (30) 1516 (29.3) 0.41
Stents, %
Bare metal stents (only) 9457 (57.9) 1819 (59.7) 1851 (60.5) 0.55 2950 (57.0) 2832 (56.3) 0.45
Drug-eluting stents 6866 (42.1) 1228 (40.3) 1211 (39.5) 0.55 2224 (43.0) 2201 (43.7) 0.45
Laboratory parameters
Hemoglobin, g/dL 14.121.72 14.591.59 14.591.63 0.96 13.851.72 13.841.71 0.88
Glomerular filtration rate,
mL/min per 1.73 m2§
8126 8928 8826 0.52 7724 7826 0.37
Data are mean (SD) or number (percentage), as appropriate. ACE indicates angiotensin-converting enzyme; GP IIbIIa inhibitors, glycoprotein IIb/IIIa inhibitors; LMWH, low-molecular-weight
heparin; MI, myocardial infarction; NSTEMI, non-ST-segment elevation myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST-segment elevation myocardial infarction;
UA, unstable angina.
*Nonsmokers were classiﬁed as current nonsmokers and former smokers.
†P values were based on Student t tests, Mann–Whitney U tests or v2 tests, as appropriate.
‡As initial reperfusion strategy.
§Estimated by applying Modiﬁcation of Diet in Renal Disease Study (MDRD) equation.
Table 2. Clinical Outcomes in Smokers Vs Nonsmokers
Smoking Status
Events
Current Smokers
(n=6394)
Nonsmokers
(n=10 862) Adjusted HR (95% CI) P Value
Cardiovascular death, MI, or stroke 204 (3.2) 514 (4.7) 0.91 (0.76–1.09) 0.30
Cardiovascular death 83 (1.3) 242 (2.2) 0.87 (0.66–1.14) 0.31
MI 117 (1.8) 280 (2.6) 0.88 (0.69–1.12) 0.29
Stroke 18 (0.3) 48 (0.4) 1.09 (0.60–1.97) 0.79
Stent thrombosis 112 (1.8) 221 (2.0) 1.03 (0.80–1.33) 0.80
Major bleed 71 (1.1) 166 (1.5) 1.32 (0.97–1.79) 0.07
Severe bleed 59 (0.9) 108 (1.0) 1.48 (1.04–2.11) 0.03
Data are numbers (%), unless otherwise indicated. HR (95% CI) indicates hazard ratio (95% conﬁdence interval); MI, myocardial infarction.
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smokers than in nonsmokers. In active smokers, the primary
outcome of cardiovascular death, MI, and stroke, was reduced
by 34% (95% CI, 0.50–0.87), without an apparent increase in
major bleeding. By contrast, this beneﬁt was not observed in
nonsmokers, but there was an increase in major bleeding in
those patients. Stent thrombosis was signiﬁcantly reduced in
both current smokers and nonsmokers. Overall, the double-
dose clopidogrel regimen might be more effective in heavy
smokers (consuming ≥20 cigarettes/d). Compared with non-
smokers, current smokers with an ACS were approximately 1
decade younger, had fewer concomitant diseases, and
presented more frequently with a STEMI, and had lower
absolute rates of the primary outcome. However, despite the
younger age, the rates of stent thrombosis were similar in
current smokers and nonsmokers.
The clinical efﬁcacy of clopidogrel in smokers and
nonsmokers with ACS and the “smoker’s paradox” remain
controversial topics. Several studies have shown signiﬁcant
interactions in outcomes among current smokers versus
nonsmokers treated with clopidogrel.8,19–21 An analysis of
the CLARITY-TIMI (Clopidogrel and Adjunctive Reperfusion
Therapy-Thrombolysis in Myocardial Infarction) 28 trial
revealed signiﬁcantly lower risk for repeat ischemic events
in smokers, who smoked at least 10 cigarettes/d and were
additionally treated with clopidogrel to aspirin, compared with
nonsmokers.19 In an analysis from the CHARISMA (Clopido-
grel for High Atherothrombotic Risk and Ischemic Stabiliza-
tion, Management, and Avoidance) trial, clopidogrel therapy
among current smokers was related to a 32% reduction in all-
cause mortality compared with current smokers treated with
placebo (4.9% versus 7.2%, respectively, P for interac-
tion=0.018). Additionally, a post hoc analysis of the CAPRIE
(Clopidogrel versus Aspirin in Patients at Risk of Ischemic
Events) trial was in line with those studies by indicating that
patients in the clopidogrel-treated smoker group had a
signiﬁcantly lower rate of the primary outcome (consisting
of ischemic stroke, MI, or vascular death) compared with the
nonsmoker group (P for interaction=0.01).21 Those results
were lately questioned by a pooled analysis including 1314
patients undergoing PCI, which found no signiﬁcant differ-
ences in platelet reactivity in current and nonsmokers treated
with clopidogrel after adjusting for hemoglobin levels.22 This
Figure 1. Outcomes for the clopidogrel dose comparison according to smoking status (current smokers vs nonsmokers). Data are number (%),
unless otherwise indicated. CV indicates cardiovascular; HR (95% CI), hazard ratio (95% conﬁdence interval); MI, myocardial infarction.
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association and its clinical implications remain partially unclear
and require further investigation. In this context, our analysis
may render important additional insights about clopidogrel’s
activity and efﬁcacy among smokers and nonsmokers.
Smoking negatively inﬂuences the coagulation system at
multiple levels: ﬁrst, it triggers platelet aggregation; second, it
promotes a procoagulatory state with increased levels of
factor VII and ﬁbrinogen, but also decreased ﬁbrinolytic
activity; third, smoking causes endothelial dysfunction, which
also impairs healing of the endothelium after stenting and in
turn increases the risk for stent thrombosis and in-stent
restenosis.23,24
The pharmacokinetics and pharmacodynamics of clopido-
grel may be inﬂuenced by multiple factors, including smoking
status, genetic polymorphisms, and other medications metab-
olized through the cytochrome P450 system.19,21,25–29
A
B
Figure 2. Kaplan–Meier curves for the primary outcome of cardiovascular death, myocardial infarction, or
stroke (A) and major bleeding (B) in current smokers and nonsmokers receiving either a standard (Std.) or
double-dose clopidogrel regimen. No. indicates number.
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Smoking, in particular, directly promotes the activity of
cytochrome P450 (CYP) 1A2 and 2B6, which are important
isoenzymes for the metabolic activation of clopido-
grel.19,21,26,29 Consequently, a higher clopidogrel dose in
current smokers may result in a higher level of its active
metabolite, resulting in a greater antiplatelet effect.
Regarding the newer antiplatelet agents and their inter-
action with smoking, the recently published PARADOX
(Prospective, Randomized Trial of Clopidogrel and Prasugrel
in Smokers and Non-Smokers) study indicated that prasugrel
had a greater active metabolite level and pharmacodynamic
efﬁcacy compared with clopidogrel irrespective of the smok-
ing status.29 The same applies for ticagrelor, which is more
effective than clopidogrel, regardless in both smokers and
nonsmokers.9 In terms of clinical outcomes, no interactions
were found between non- and current smokers with an ACS in
the Trial to Assess Improvement in Therapeutic Outcomes by
Optimizing Platelet Inhibition with Prasugrel–Thrombolysis in
Myocardial Infarction (TRITON-TIMI) 38 trial.30 However, the
Targeted Platelet Inhibition to Clarify the Optimal Strategy
to Medically Manage Acute Coronary Syndromes (TRILOGY-
ACS) trial, which enrolled ACS patients age <75 years not
Table 3. Efﬁcacy and Safety Outcomes for the Clopidogrel Dose Comparison According to Smoking Patterns and Intensity
Clopidogrel Dose
Standard Vs Double-Dose
Clopidogrel
Events Smoking Status*
Standard
(n=8702)
Double
(n=8554) Adjusted HR (95% CI) P Value
P for
Interaction
Cardiovascular
death, MI, or
stroke
Nonsmokers 269 (4.9) 245 (4.6) 0.96 (0.80–1.14) 0.608 0.016
Current smokers, <10 cigarettes/d 17 (4.3) 22 (5.2) 1.21 (0.64–2.28) 0.567
Current smokers, 10 to 19 cigarettes/d 27 (3.6) 22 (2.9) 0.78 (0.45–1.37) 0.393
Current smokers, ≥20 cigarettes/d 78 (3.8) 38 (1.9) 0.48 (0.33–0.71) <0.0001
Cardiovascular
death
Nonsmokers 120 (2.2) 122 (2.3) 1.08 (0.83–1.39) 0.573 0.314
Current smokers, <10 cigarettes/d 8 (2) 10 (2.3) 1.11 (0.43–2.87) 0.823
Current smokers, 10 to 19 cigarettes/d 10 (1.3) 6 (0.8) 0.58 (0.21–1.60) 0.292
Current smokers, ≥20 cigarettes/d 30 (1.5) 19 (0.9) 0.62 (0.35–1.11) 0.106
MI Nonsmokers 152 (2.8) 128 (2.4) 0.89 (0.70–1.12) 0.312 0.026
Current smokers, <10 cigarettes/d 9 (2.3) 12 (2.9) 1.31 (0.55–3.11) 0.545
Current smokers, 10 to 19 cigarettes/d 17 (2.3) 15 (2) 0.85 (0.42–1.70) 0.645
Current smokers, ≥20 cigarettes/d 47 (2.3) 17 (0.8) 0.37 (0.21–0.64) <0.0001
Stroke Nonsmokers 26 (0.5) 22 (0.4) 0.91 (0.51–1.62) 0.756 0.999
Current smokers, <10 cigarettes/d 1 (0.3) 0 (0) 0 (0–0) 0.997
Current smokers, 10 to 19 cigarettes/d 2 (0.3) 2 (0.3) 0.87 (0.12–6.20) 0.890
Current smokers, ≥20 cigarettes/d 7 (0.3) 6 (0.3) 0.85 (0.28–2.52) 0.765
Stent thrombosis Nonsmokers 127 (2.3) 94 (1.8) 0.79 (0.60–1.03) 0.081 0.017
Current smokers, <10 cigarettes/d 4 (1) 9 (2.1) 2.27 (0.69–7.45) 0.175
Current smokers, 10 to 19 cigarettes/d 14 (1.9) 11 (1.4) 0.77 (0.35–1.71) 0.527
Current smokers, ≥20 cigarettes/d 54 (2.6) 20 (1) 0.36 (0.22–0.61) <0.0001
Major bleed Nonsmokers 59 (1.1) 107 (2) 1.89 (1.37–2.60) <0.0001 0.018
Current smokers, <10 cigarettes/d 6 (1.5) 4 (0.9) 0.66 (0.19–2.36) 0.525
Current smokers, 10 to 19 cigarettes/d 17 (2.3) 12 (1.6) 0.66 (0.32–1.38) 0.272
Current smokers, ≥20 cigarettes/d 17 (0.8) 15 (0.7) 0.91 (0.45–1.85) 0.804
Severe bleed Nonsmokers 41 (0.7) 67 (1.3) 1.71 (1.16–2.52) 0.007 0.222
Current smokers, <10 cigarettes/d 4 (1) 2 (0.5) 0.48 (0.09–2.64) 0.400
Current smokers, 10 to 19 cigarettes/d 13 (1.8) 12 (1.6) 0.87 (0.40–1.90) 0.722
Current smokers, ≥20 cigarettes/d 14 (0.7) 14 (0.7) 1.05 (0.49–2.25) 0.890
Data are numbers (%), unless otherwise indicated. HR (95% CI) indicates hazard ratio (95% conﬁdence interval); MI, myocardial infarction.
*Patients (n): Nonsmokers, 6747; light smokers (<10 cigarettes/d), 1368; moderate smokers (10–19 cigarettes/d), 1368; and heavy smokers (≥20 cigarettes/d), 6594.
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undergoing revascularization, revealed a signiﬁcant interac-
tion between smokers and nonsmokers treated with prasugrel
compared with clopidogrel with regard to the composite
primary end point of death from cardiovascular causes,
nonfatal MI, or stroke. In fact, this outcome was reduced by
46% among smokers receiving prasugrel instead of clopido-
grel (HR 0.54 [95% CI, 0.39–0.74]), whereas in nonsmokers
this effect was not seen (HR 1.06 [95% CI, 0.90–1.24]; P for
interaction<0.0001).31
If a double- compared with a standard-dose clopidogrel
regimen reduces the risk of cardiovascular death, MI, or stroke
in all current versus nonsmokers with ACS, also including
patients receiving onlymedical management has been tested in
the CURRENT-OASIS 7 patient population, as published
earlier.15 There, we found a nonsigniﬁcant reduction of the
primary outcome with the double- versus standard dosing
regimen (2.9% versus 3.6%; HR 0.80 [95% CI, 0.63–1.02,
P=0.07]) among current smokers (n=8373), but no signiﬁcant
difference among nonsmokers (n=16 701, 4.8% versus 4.8%;
HR 0.99 [95%CI, 0.86–1.14], P=0.89; P for interaction=0.14).15
Although there seems to be a trend suggesting a possible
advantage of the higher clopidogrel regimen in all current
smokers with ACS presentation, irrespective of their PCI status,
more data are required to conﬁrm this hypothesis.
Finally, one needs to take into account that the double-dose
clopidogrel regimen also increased the rates of hemorrhagic
events. However, the bleeding rates were lower among current
smokers compared with nonsmokers. This might be partially
explained by the differences in the baseline characteristics
between current and nonsmokers, including among others,
higher prevalence of females, higher age, worse renal function,
and lower hemoglobin levels among the nonsmoking patients,
which are known predictors for bleeding events in ACS
patients.32,33 Since bleeding complications are associated
with worse outcomes and high mortality rates in ACS patients
treated with PCI, physicians should aim for a personalized
antithrombotic strategy, which carefully weighs the treatment
risks and beneﬁts.32,33 As indicated by our study, this seems
also to apply for the clopidogrel dosing in ACS patients.
Our results should be interpreted in the context of some
limitations. First, this is a subgroup analysis and should
therefore be interpreted as hypothesis-generating. However, it
is noteworthy that the sample size is very large, the treatment
groups are randomized, and the interaction P value for
treatment effect in current smokers and nonsmokers was
signiﬁcant. Second, we are also not able to provide pharma-
cokinetic, dynamic, and genetic data, which may have
rendered additional insights about clopidogrel’s interaction
with smoking. Third, follow-up was only 30 days, which is
relatively short. However, the highest risk of thrombotic
events after ACS occurs within the ﬁrst 30 days. Finally,
information about post-PCI smoking habits has not been
collected, which might have also added important insights in
this study’s context.
Conclusions
Compared with the standard dose, a 7-day double-dose
regimen of clopidogrel reduced the rate of major cardiovas-
cular events in the ACS setting signiﬁcantly more among
current smokers than in nonsmokers. It also had less of an
effect on increased risk for major bleeding in current smokers
than in nonsmokers. The double-dose clopidogrel strategy
appeared to be particularly effective in heavy smokers
(consuming ≥20 cigarettes/d). Therefore, a more intensive
antiplatelet inhibition may be especially beneﬁcial in smokers
presenting with ACS who are referred for early PCI. These
data also suggest that a personalized clopidogrel-dosing
strategy considering risk factors for early adverse outcomes
after PCI in ACS patients should be applied.
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SUPPLEMENTARY MATERIAL 
 
Table S1  Baseline characteristics grouped by smoking status 
 
 
Overall 
(n=17,263) 
Non-smoker† 
(n=10,862) 
Current smoker 
(n=6,394) P-value
* 
Age (years) 61.2±11.7 64.6±11.2 55.3±9.9 <0.0001 
Age >75years (%) 2,188 (12.7) 1,999 (18.4) 186 (2.9%) <0.0001 
Males (%) 13,029 (75.5) 7,655 (70.5) 5,369 (84.0) <0.0001 
Presentation (%):     
STEMI 6,364 (36.9) 3,469 (31.9) 2,889 (45.2) <0.0001 
UA/ NSTEMI 10,899 (63.1) 7,393 (68.1) 3,505 (54.8) <0.0001 
Diabetes mellitus (%) 3,844 (22.3) 2,868 (26.4) 974 (15.2) <0.0001 
Hypertension (%) 10,197 (59.1) 7,162 (65.9) 3,031 (47.4%) <0.0001 
Dyslipidemia (%) 6,953 (40.3) 4,661 (42.9) 2,290 (35.8) <0.0001 
Previous MI (%) 2,933 (17.0) 2,157 (19.9) 775 (12.1) <0.0001 
Previous PCI (%) 2,515 (14.6) 1,901 (17.5) 613 (9.6) <0.0001 
Peripheral arterial disease (%) 753 (4.4) 482 (4.4) 269 (4.2) 0.47 
Antithrombotics prior to 
randomization (%):     
Aspirin 6,444 (37.3) 4,862 (44.8) 1,580 (24.7) <0.0001 
Clopidogrel 3,494 (20.2) 2,519 (23.2) 973 (15.2) <0.0001 
Unfractionated heparin 6,685(38.7) 4,236(39) 2,443(38.2) 0.31 
LMWH 6,619(38.4) 4,047(37.3) 2,571(40.2) <0.0001 
Fondaparinux 599(3.5) 382(3.5) 217(3.4) 0.67 
GP IIbIIIa inhibitors 4,383(25.4) 2,600(23.9) 17,80(27.8) <0.0001 
Fibrinolytics‡ 534 (8.4) 277 (8.0) 257 (8.9) 0.19 
Antithrombotics administered 
during PCI and hospital admission 
(%): 
    
Unfractionated heparin 15,151 (87.8) 9,503 (87.5) 5,642 (88.2) 0.15 
LMWH 8’628 (50.0) 5’244 (48.3) 3’381 (52.9) <0.0001 
Fondaparinux 779 (4.5) 505 (4.6) 274 (4.3) 0.27 
Bivalirudin 960 (5.6) 658 (6.1) 302 (4.7) <0.0001 
GP IIbIIIa inhibitors 7’010 (40.6) 4’223 (38.9) 2’784 (43.5) <0.0001 
Post-randomization therapy (%):     
β-blockers 14,555 (84.3) 9,132 (84.1) 5,420 (84.8) 0.23 
ACE-inhibitors 11,989 (69.5) 7,437 (68.5) 4,550 (71.2) <0.0001 
AT-2-antagonists 1,588 (9.2) 1,162 (10.7) 425 (6.6) <0.0001 
Ca-channel blockers 2,352 (13.6) 1,699 (15.6) 653 (10.2) <0.0001 
Statins 15,575 (90.2) 9,712 (89.4) 5,859 (91.6) <0.0001 
Proton-pump inhibitors 5,295 (39.9) 3,206 (39.8) 2,087 (40.1) 0.74 
Lesions treated (%): 17,671 11,248 - 6,418 - 
Left main 279(1.6) 191 (1.7) 87 (1.4)  
Left anterior descending 6,130 (34.7) 4,076 (36.2) 2,054 (32.0)  
Left circumflex 4,656 (26.3) 2,900) (25.8) 1,756 (27.4)  
Right coronary artery 6,161 (34.9) 3,706 (32.9) 2,451 (38.2)  
Saphenous vein / arterial graft 445 (2.5) 375 (3.3) 70 (1.1)  
Visible angiographic thrombus 
before PCI 
5,466/16675 
(32.8) 
3,111/10484 
(29.7) 
2,353/6186 
(38.0) <0.0001 
Stents (%):     
Bare metal stents (only) 9,457 (57.9) 5,782 (56.6) 3,670 (60.1) <0.0001 
Drug eluting stents 6,866 (42.1) 4,425 (43.4) 2,439 (39.9) <0.0001 
Laboratory parameters:     
Hemoglobin (g/dL) 14.1±1.7 13.8±1.7 14.6±1.6 <0.0001 
Glomerular filtration rate 
(mL/min/1.73m2) § 
81±26 77±25 88±27 <0.0001 
 
Data are mean (standard deviation) or number (percentage), as appropriate. GP IIbIIa inhibitors = Glycoprotein IIb/IIIa 
inhibitors; LMWH = Low molecular weight heparin; MI = Myocardial infarction; NSTEMI = Non-ST-segment elevation 
myocardial infarction; PCI = Percutaneous coronary intervention; STEMI = ST-segment elevation myocardial infarction; UA = 
Unstable angina. 
* P values were based on student’s t-tests, Mann-Whitney U- tests or Chi-square tests, as appropriate.  
† Non-smokers were classified as current non-smokers and former smokers. 
‡ As initial reperfusion strategy. 
§ Estimated by applying Modification of Diet in Renal Disease Study (MDRD) equation. 
 
Table S2 Baseline characteristics grouped by clopidogrel regimen 
(standard versus double-dose) 
 
 
Standard-dose 
clopidogrel regimen 
(n=8,702) 
Double-dose 
clopidogrel regimen 
 (n=8,554) 
P-value* 
Age (years) 61.2±11.6 61.2±11.7 0.69 
Age >75years (%) 1,092 (12.5) 1,096 (12.8) 0.61 
Males (%) 6,520 (74,9) 6,509 (76.0) 0.086 
Presentation (%):    
STEMI 3,183 (36.6) 3,181 (37.2) 0.42 
UA/ NSTEMI 5,520 (63.4) 5,379 (62.8) 0.42 
Smoking status (%):    
Current smoker 3189 (36.6) 3205 (37.5) 0.26 
Never smoked 3441 (39.5) 3306 (38.6) 0.23 
Former smoker 2072 (23.8) 2043 (23.9) 0.91 
Diabetes mellitus (%) 1,934 (22.2) 1,910 (22.3) 0.89 
Hypertension (%) 5,117 (58.8) 5,080 (59.4) 0.45 
Dyslipidemia (%) 3,506 (40.3) 3,447 (40.3) 0.99 
Previous MI (%) 1,459 (16.8) 1,474 (17.2) 0.43 
Previous PCI (%) 1,264 (14.5) 1,251 (14.6) 0.87 
Peripheral arterial disease (%) 381 (4.4) 372 (4.3) 0.92 
Antithrombotics prior to 
randomization (%):    
Aspirin 3,237 (37.2) 3,207 (37.5) 0.71 
Clopidogrel 1,755 (20.2) 1,739 (20.3) 0.81 
Unfractionated heparin 3,371(38.7) 3,314(38.7) 0.97 
LMWH 3,323(38.2) 3,296(38.5) 0.68 
Fondaparinux 308(3.5) 291(3.4) 0.61 
GP IIbIIIa inhibitors 2,192(25.2) 2,191(25.6) 0.55 
Fibrinolytics‡ 270 (8.5) 264 (8.3) 0.79 
Antithrombotics administered 
during PCI and hospital admission 
(%): 
   
Unfractionated heparin 7’624 (87.6) 7’527 (87.9) 0.51 
LMWH 4’305 (49.5) 4’323 (50.5) 0.17 
Fondaparinux 400 (4.6) 379 (4.4) 0.59 
Bivalirudin 479 (5.5) 481 (5.6) 0.74 
GP IIbIIIa inhibitors 3’507 (40.3) 3’503 (40.9) 0.41 
Post-randomization therapy (%):    
β-blockers 7,275 (83.6) 7,280 (85.0) 0.009 
ACE-inhibitors 6,028 (693) 5,961 (69.6) 0.60 
AT-2-antagonists 839 (9.6) 749 (8.8) 0.04 
Ca-channel blockers 1,197 (13.8) 1,155 (13.5) 0.61 
Statins 7,860 (90.3) 7,715 (90.1) 0.66 
Proton-pump inhibitors 2,651 (39.6) 2,644 (40.2) 0.49 
Lesions treated (%): 8900 8771  
Left main 140 (1.6) 139 (1.6) - 
Left anterior descending 3,053 (34,3) 3,077 (35.1)  
Left circumflex 2,374 (26.7) 2,282 (26)  
Right coronary artery 3,124 (35.1) 3,037 (34.6)  
Saphenous vein / arterial graft 209 (2.3) 236 (2.7)  
Visible angiographic thrombus 
before PCI 
2,747/8399 (32.7) 2,719/8276 (32.9) 0.84 
Stents (%):    
Bare metal stents (only) 4,769 (58.0) 4,688 (57.9) 0.86 
Drug eluting stents 3,453 (42.0) 3,413 (42.1) 0.86 
Laboratory parameters:    
Hemoglobin (g/dL)   14.1±1.7 14.1±1.7 0.96 
Glomerular filtration rate 
(mL/min/1.73m2) § 81± 26 82±27 0.62 
 
Data are mean (standard deviation) or number (percentage), as appropriate. GP IIbIIa inhibitors = Glycoprotein IIb/IIIa 
inhibitors; LMWH = Low molecular weight heparin; MI = Myocardial infarction; NSTEMI = Non-ST-segment elevation 
myocardial infarction; PCI = Percutaneous coronary intervention; STEMI = ST-segment elevation myocardial infarction; UA = 
Unstable angina. 
* P values were based on student’s t-tests, Mann-Whitney U- tests or Chi-square tests, as appropriate.  
† Non-smokers were classified as current non-smokers and former smokers. 
‡ As initial reperfusion strategy. 
§ Estimated by applying Modification of Diet in Renal Disease Study (MDRD) equation. 
